- recruitingPHASE1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
This study is testing a new medicine, PF-07799933, for advanced cancers with a specific gene change (BRAF alterations). It aims to see how safe and effective it is, sometimes combined with other medicines, for people when usual treatments haven't worked.
United States · Canada · Israel - recruiting
Monitoring of Patients With Low-grade Gliomas Using Circulating miRNA
This study looks at using tiny molecules called microRNAs from blood samples to find out if glioma brain tumours are coming back earlier. This could help doctors treat Grade 2 and 3 brain tumours sooner, giving patients better care.
France - not yet recruitingNA
Mapping Molecular Markers of Brain Tumour Activity Using MRI
This study uses new MRI scans to find early signs of brain tumour growth. It helps doctors see how active a tumour is and predict its changes, aiming to improve future diagnosis and treatment planning for gliomas by comparing scans with tiny tissue samples.
United Kingdom - not yet recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This study looks at two drugs called dabrafenib and trametinib for various cancers with a specific gene change (BRAF V600). These drugs are already approved for some cancers and researchers want to see if they can help people with other rare cancers or cancers with this same change.
United Kingdom - recruiting
Tessa Jowell BRAIN MATRIX - Platform Study
This study aims to better understand brain tumours (gliomas) by carefully examining tumour and blood samples. The goal is to set up a system across the UK to quickly identify the exact type of tumour and help test new, tailored treatments based on each person's unique tumour characteristics.
United Kingdom - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This study is testing a cancer drug called capmatinib to see if it can help adults with different types of cancer that share a specific genetic change (MET mutation). It's already approved for some lung cancers, and now researchers want to know if it works for other cancers too.
United Kingdom - recruitingPHASE3
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
This study looks at a new drug, dordaviprone (ONC201), for a type of brain tumour called H3 K27M-mutant diffuse glioma. It aims to see if the drug, given after radiotherapy, can help people live longer and slow down the tumour's growth.
United States · Argentina · Australia - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
This study is testing a drug called entrectinib for different cancers in adults and children. It focuses on cancers with a specific change in their cells, called ROS1 gene fusion, to see if entrectinib can be a new treatment option.
United Kingdom - recruitingNA
Platelets Activation in Brain Neoplasms
This study looks at how tiny blood cells called platelets might affect brain tumours. We want to see if platelets are found inside these tumours and if they play a role in how the tumour grows or responds to treatment. The aim is to find new ways to improve anti-cancer therapies.
France - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This study is for adults with specific cancers that have a change called BRAF V600. It's testing if two drugs, vemurafenib and cobimetinib, already used for a type of skin cancer, can help treat these other cancers. The goal is to find new treatments for patients.
United Kingdom - not yet recruitingNA
Protoporphyrin Imaging in Multispectral Evaluation of Resections
This study looks at using a new camera on a surgery microscope to get better pictures of brain tumours during an operation. It aims to help surgeons see the tumour more clearly and remove as much of it as possible, without changing the surgery itself.
Austria · Germany · Switzerland - active not recruitingPHASE1
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
This study is for adults with a brain tumour called glioma, where previous treatments haven't worked. It's looking to find the safest highest dose of a new drug, BI 764532, which helps your immune system fight the cancer.
United States · Austria · Germany - authorisedPhase I and Phase II (Integrated)- Other
uPAR PET/MRI in glioma
This study is looking at a new type of body scan (called a uPAR-PET/MRI) for people with a brain tumour called glioma. It uses a special tracer ([68Ga]NOTA-AE105) to see how much of a certain protein (uPAR) is in the tumour, hoping to help understand the disease better.
Denmark - authorisedHuman Pharmacology (Phase I)- Other
Repurposed Drugs in Research and Cancer Clinical Trials. The ReDiReCCT trial Vemurafenib
The ReDiReCCT trial is looking at a medicine called Vemurafenib for people with a type of brain tumour called glioma. This early-stage study wants to see if this existing medicine can be safely used for this condition and how it affects the body.
Netherlands - recruitingNA
FIH Clinical Investigation of Graphene Electrodes for Brain Mapping
This study tests new, very thin brain sensors made from a material called graphene. Doctors want to see if these sensors are safe and work well during brain tumour surgery to help protect important brain functions.
United Kingdom - recruiting
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
This study looks at how new ways of classifying brain tumours (cIMPACT-NOW and 2021 WHO) help us understand treatment and what to expect. Researchers want to see if these new classifications group patients better and lead to clearer treatment guidelines for different types of brain tumours.
Austria · Belgium · France